Eris LifesciencesNSE:ERIS -0.50%91 EBITDA Margin % is 36.50% as of Mar. 2026, which is 0% below its 10-year median of 36.55. GuruFocus rates NSE:ERIS with a GF Score™ of 91/100 and a GF Value™ of ₹1,642.12 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 952 Drug Manufacturers companies, Eris Lifesciences ranks better than 91.18% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Eris Lifesciences's EBITDA for the
three
months ended in Mar. 2026 was ₹2,746 Mil. Eris Lifesciences's Revenue for the
three
months ended in Mar. 2026 was ₹7,523 Mil. Therefore, Eris Lifesciences's EBITDA margin for the quarter that ended in Mar. 2026 was 36.50%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Eris Lifesciences EBITDA Margin % Related Terms
Eris Lifesciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Eris Lifesciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eris Lifesciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eris Lifesciences EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eris Lifesciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Eris Lifesciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eris Lifesciences (NSE:ERIS) has a EBITDA Margin % of 36.50% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Eris Lifesciences and its competitors. This is near median its historical median of 36.55. Over the past decade, Eris Lifesciences' EBITDA Margin % has ranged from 32.97 to 42.13. According to the industry distribution chart, Eris Lifesciences ranks #84 out of 952 companies in the Drug Manufacturers industry, placing it in the top 8.8%.
Is Eris Lifesciences' EBITDA Margin % too high?
Eris Lifesciences' current EBITDA Margin % of 36.50% is near median its 10-year median of 36.55. Over the past 10 years, this metric has ranged from a low of 32.97 to a high of 42.13. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Eris Lifesciences' value of 36.50% is 192.7% above this industry median. Based on the distribution chart, Eris Lifesciences ranks #84 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Eris Lifesciences has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eris Lifesciences' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Eris Lifesciences ranks #84 out of 952 companies for EBITDA Margin %. This places Eris Lifesciences in the top 9% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.47. Eris Lifesciences' value of 36.50% is 192.7% above this benchmark. Historically, Eris Lifesciences' own EBITDA Margin % has ranged from 32.97 to 42.13 over the past decade. While the company's 10-year median is 36.55 vs. the industry median of 12.47, Eris Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eris Lifesciences's current EBITDA Margin % of 36.50% is 192.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Eris Lifesciences and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eris Lifesciences's current EBITDA Margin % is 36.50%, which is near median its own 10-year median of 36.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eris Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eris Lifesciences (NSE:ERIS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,642.12, compared to a current price of ₹1,459.00 — trading 11.2% below its estimated fair value. The current EBITDA Margin % is 36.50%, which is near median its 10-year median of 36.55 and 192.7% above the Drug Manufacturers industry median of 12.47. Eris Lifesciences' overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Eris Lifesciences (NSE:ERIS), the current EBITDA Margin % is 36.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eris Lifesciences (NSE:ERIS) Overvalued in 2026?
Based on GuruFocus' analysis, Eris Lifesciences stock appears to be undervalued.
The current stock price of ₹1,459.00 is trading 11.2% below its estimated GF Value™ of ₹1,642.12.
GuruFocus considers Eris Lifesciences to be Modestly Undervalued.
Key valuation signals for NSE:ERIS:
EBITDA Margin %: 36.50% (near median its 10-year median of 36.55)
GF Value™: ₹1,642.12 vs. price of ₹1,459.00 (11.2% below fair value)
Industry Position: 192.7% above the Drug Manufacturers median (#84 of 952)
No single metric tells the full story. See the NSE:ERIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast. The company works basically within India and International with the majority of revenue from India.
91GF Score
Get the complete analysis for NSE:ERIS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ERIS has been successfully added to your 
